Single-arm phase 1-2 study | Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Sotorasib Shows Clinically Meaningful Activity Among Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer – The ASCO Post

Commentary on Twitter

In a phase 1–2 trial involving patients with advanced pancreatic cancer, sotorasib (a KRAS G12C inhibitor) resulted in a response in 21% of the patients and a median progression-free survival of 4 months. https://t.co/BUepIWvx65 pic.twitter.com/i1kugfC6Nq

— NEJM (@NEJM) December 21, 2022